Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
作者： Markus Axelsson , Clas Malmeström , Martin Gunnarsson , Henrik Zetterberg , Peter Sundström
关键词:
摘要: Background: In progressive multiple sclerosis (PMS), disease-modifying therapies have not been shown to reduce disability progression.Objective: The impact from immunosuppressive therapy in PMS was ...
sagepub.com
comtecmed.com 参考文章(35)
Dorothea Buck, Bernhard Hemmer, Treatment of multiple sclerosis: current concepts and future perspectives Journal of Neurology. ,vol. 258, pp. 1747- 1762 ,(2011) , 10.1007/S00415-011-6101-2
J. R. Avasarala, J. N. Lycke, C. Malmestrom, S. Haghighi, L. Rosengren, O. Andersen, Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS Neurology. ,vol. 61, pp. 1720- 1725 ,(2003) , 10.1212/WNL.63.3.599
C. E. Teunissen, E. Iacobaeus, M. Khademi, L. Brundin, N. Norgren, M.J.A. Koel-Simmelink, M. Schepens, F. Bouwman, H. A.M. Twaalfhoven, H. J. Blom, C. Jakobs, C. D. Dijkstra, Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology. ,vol. 72, pp. 1322- 1329 ,(2009) , 10.1212/WNL.0B013E3181A0FE3F
J. A. Cohen, J. P. Antel, Does interferon beta help in secondary progressive MS Neurology. ,vol. 63, pp. 1768- 1769 ,(2004) , 10.1212/01.WNL.0000147171.32178.48
CE Teunissen, Axel Petzold, Jeffrey L Bennett, Frode S Berven, Lou Brundin, Manuel Comabella, Diego Franciotta, Jette L Frederiksen, JO Fleming, Roberto Furlan, RQ Hintzen, MD, SG Hughes, MH Johnson, Eva Krasulova, Jens Kuhle, Maria-Chiara Magnone, Cecília Rajda, Konrad Rejdak, HK Schmidt, Vincent Van Pesch, Emmanuelle Waubant, Christiane Wolf, Gavin Giovannoni, B Hemmer, Hayrettin Tumani, F Deisenhammer, A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking Neurology. ,vol. 73, pp. 1914- 1922 ,(2009) , 10.1212/WNL.0B013E3181C47CC2
DKB Li, GJ Zhao, DW Paty, University of British Columbia MS/MRI Analysis Research Group and the SPECTRIMS Study Group*, None, Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology. ,vol. 56, pp. 1505- 1513 ,(2001) , 10.1212/WNL.56.11.1505
L.E. Rosengren, J. Lycke, O. Andersen, Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit Journal of the Neurological Sciences. ,vol. 133, pp. 61- 65 ,(1995) , 10.1016/0022-510X(95)00152-R
Jerry S. Wolinsky, Ponnada A. Narayana, Paul O'Connor, Patricia K. Coyle, Corey Ford, Kenneth Johnson, Aaron Miller, Lillian Pardo, Shaul Kadosh, David Ladkani, , Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial Annals of Neurology. ,vol. 61, pp. 14- 24 ,(2007) , 10.1002/ANA.21079
N. Norgren, P. Sundstrom, A. Svenningsson, L. Rosengren, T. Stigbrand, M. Gunnarsson, Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology. ,vol. 63, pp. 1586- 1590 ,(2004) , 10.1212/01.WNL.0000142988.49341.D1
JA Cohen, GR Cutter, JS Fischer, AD Goodman, FR Heidenreich, MF Kooijmans, AW Sandrock, RA Rudick, JH Simon, NA Simonian, EC Tsao, JN Whitaker, IMPACT Investigators, None, Benefit of interferon β-1a on MSFC progression in secondary progressive MS Neurology. ,vol. 59, pp. 679- 687 ,(2002) , 10.1212/WNL.59.5.679